Physicians' Academy for Cardiovascular Education

Heart Failure

Follow the news, literature, and elearning on new developments in the management of Heart Failure.

RAASi as a fundamental pillar in HF

10' education - Oct. 4, 2021 - Prof. Andrew Coats, MD

Risks associated with hyperkalemia

10' education - Sep. 16, 2021 - Prof. Stefan Anker, MD, PhD

Ground-breaking HF trial with evidence for SGLT2i at EF>40%

3' education - Aug. 29, 2021 - Prof. Frank Ruschitzka, MD

Kidney and HF outcomes with SGLT2i across EF spectrum in HF

3' education - Aug. 28, 2021 - Prof. Rudolf de Boer, MD, PhD

What is new in the 2021 ESC HF guidelines regarding patients with EF>40%?

3' education - Aug. 27, 2021 - Prof. Carolyn Lam, MD, PhD

Exciting findings of a pooled analysis of two large HF trials with SGLT2i

3' education - Aug. 27, 2021 - Milton Packer, MD

Another chapter in the SGLT2i book

3' education - Aug. 27, 2021 - Prof. Rudolf de Boer, MD, PhD

Phenotypic clusters in HFpEF

5' education - July 28, 2021 - Alicia Uijl, PhD

Patient profiling in HFrEF to tailor therapy

5' education - June 21, 2021 - Pardeep Jhund, MD, PhD

No definite difference for primary endpoint but proven safety with ARNI in MI patients

5' education - May 15, 2021 - Prof. Marc Pfeffer, MD, PhD

Prognostic value of natriuretic peptides in patients with HF and kidney dysfunction

10' education - May 11, 2021 - Prof. James Januzzi, MD

Treatment algorithms for HFpEF

10' education - May 4, 2021 - Prof. John Cleland, MD

Recommendations for treatment algorithm of HFrEF

10' education - Apr. 26, 2021 - Andrew Coats, MD

Effects of iron deficiency on outcomes in HF

10' education - Apr. 6, 2021 - Adrian F. Hernandez, MD

Two medical therapies elevated to front line in 2021 update HF ECDP

5' education - Feb. 1, 2021 - Prof. James Januzzi, MD

Clinical outcome trial with IV iron in patients with iron deficiency, stabilized after acute HF

3' education - Dec. 15, 2020 - Prof. Peter van der Meer, MD, PhD

Ferric carboxymaltose in patients with iron deficiency after acute HF to reduce HF hospitalizations

5' education - Nov. 23, 2020 - Prof. Piotr Ponikowski, MD, PhD

The six pillars of therapy in HFrEF

3' education - Nov. 15, 2020 - Prof. Marc Pfeffer, MD, PhD

Introduction: Optimizing RAASi treatment through long-term potassium control

10' education - Oct. 22, 2020 - Prof. Peter van der Meer, MD

Novel potassium binders to improve management of chronic HF

10' education - Oct. 21, 2020 - Prof. Javed Butler, MD - Online CME

Understanding risk of hyperkalemia in heart failure

10' education - Oct. 8, 2020 - Prof. Piotr Ponikowski, MD, PhD - Online CME

Heart failure, a multimorbid syndrome: An increasing challenge to manage

10' education - Sep. 21, 2020 - Prof. Carolyn Lam, MD, PhD - Online CME

New potassium binders for management of hyperkalemia in HF

10' education - Sep. 16, 2020 - Prof. Faiez Zannad, MD

Setting a patient on the right track following hospitalization for ADHF

15' education - Sep. 14, 2020 - Alexander Cadenbach, MD and prof. Mark Petrie, MD - Online CME

Iron deficiency in patients with heart failure

10' education - Sep. 8, 2020 - Niels Grote Beverborg, MD, PhD

Incredible consistency between two SGLT2i trials in HFrEF

3' education - Sep. 7, 2020 - Milton Packer, MD

How to diagnose and treat amyloidosis?

10' education - Sep. 1, 2020 - Prof. Peter van der Meer, MD, PhD

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD

Succes with SGLT2 inhibitor in HFrEF for all three end points

3' education - Aug. 29, 2020 - Milton Packer, MD

Remarkably similar findings with another SGLT2i in HFrEF

3' education - Aug. 29, 2020 - Prof. John McMurray

SGLT2i reduces cardiorenal outcomes in HFrEF irrespective of baseline NT-proBNP

Literature - Oct. 18, 2021 - Januzzi JL, et al. - J Am Coll Cardiol 2021

Reduction of CV and renal outcomes by empagliflozin in HFrEF patients in the EMPEROR-Reduced trial was independent of baseline NT-proBNP levels. Empagliflozin reduced NT-proBNP levels, which was associated with a reduction in adverse outcomes.

E-learning Potassium binding in heart failure management

Accredited E-Learning

Online-CME - This course consists of 3 parts.

In this series, three experts in heart failure discuss the dilemma of discontinuation/reducing RAASi and lose the benefits of RAASi vs. continued RAASi and accept the presence of hyperkalemia. Moreover, the option of novel potassium binders is presented, when and how to use these agents?

RAASi as a fundamental pillar in HF

10' education - Oct. 4, 2021 - Prof. Andrew Coats, MD
Prof. Coats discusses the dilemma when hyperkalemia occurs in HF: discontinuation/reducing RAASi and lose the benefits of RAASi vs. continued RAASi and accept the presence of hyperkalemia.

Prof. Coats discusses the dilemma when hyperkalemia occurs in HF patients: discontinuation/reducing RAASi and lose the benefits of RAASi vs. continued RAASi and accept the presence of hyperkalemia.

Risks associated with hyperkalemia

10' education - Sep. 16, 2021 - Prof. Stefan Anker, MD, PhD
Hyperkalemia is a major clinical problem. Prof. Stefan Anker talks about problems and risk associated with hyperkalemia.

Hyperkalemia is a major clinical problem. Prof. Stefan Anker talks about problems and risk associated with hyperkalemia.

Low testing rates for iron deficiency in patients with HF

Literature - Sep. 15, 2021 - Becher PM et al. - Eur J Heart Fail. 2021

In SwedeHF, a nationwide HF registry in Sweden, approximately 1 in 4 patients with HF were tested for iron deficiency (ID). ID was present in half of the tested population. 1 in 5 patients with ID received ferric carboxymaltose.

FDA Breakthrough Therapy Designation for SGLT2i in HFpEF

News - Sep. 14, 2021

The FDA has granted Breakthrough Therapy Designation to empagliflozin as an investigational treatment for patients with HFpEF, following the results from the EMPEROR-Preserved trial.

SGLT2 inhibitor reduces epicardial adipose tissue in nondiabetic patients with HFrEF

Literature - Sep. 13, 2021 - Requena-Ibáñez JA et al. - JACC Heart Fail. 2021

Empagliflozin significantly reduced epicardial adipose tissue, subcutaneous adipose tissue, myocardial extracellular volume, matrix volume, cardiomyocyte volume, aortic stiffness and several inflammatory biomarkers, compared to placebo in nondiabetic patients with HFrEF.

Ground-breaking HF trial with evidence for SGLT2i at EF>40%

3' education - Aug. 29, 2021 - Prof. Frank Ruschitzka, MD
After prof. Ruschitzka summarizes the EMPEROR-Preserved trial, he calls on us to reconsider our vision on dichotimizing HF by a threshold of EF.

ESC 2021 After prof. Ruschitzka summarizes the EMPEROR-Preserved trial, he calls on us to reconsider our vision on dichotimizing HF by a threshold of EF.

Kidney and HF outcomes with SGLT2i across EF spectrum in HF

3' education - Aug. 28, 2021 - Prof. Rudolf de Boer, MD, PhD
In the EMPEROR-Pooled analysis, the efffect of empagliflozin on kidney and HF outcomes was assessed across the full spectrum of ejection fraction in HF. Prof. De Boer talks about the exciting findings.

ESC 2021 In the EMPEROR-Pooled analysis, the efffect of empagliflozin on kidney and HF outcomes was assessed across the full spectrum of ejection fraction in HF. Prof. De Boer talks about the exciting findings.

What is new in the 2021 ESC HF guidelines regarding patients with EF>40%?

3' education - Aug. 27, 2021 - Prof. Carolyn Lam, MD, PhD
Prof. Carolyn Lam discusses the major changes in the 2021 ESC/HFA heart failure guidelines regarding diagnosis and treatment of patients with ejection fraction above 40%.

ESC 2021 Prof. Carolyn Lam discusses the major changes in the 2021 ESC/HFA heart failure guidelines regarding diagnosis and treatment of patients with ejection fraction above 40%.

Exciting findings of a pooled analysis of two large HF trials with SGLT2i

3' education - Aug. 27, 2021 - Milton Packer, MD
Data of two large trials with empagliflozin in patients with heart failure, EMPEROR-Reduced and EMPEROR-Preserved, were pooled for analysis. Milton Packer shares the findings of EMPEROR-Pooled.

ESC 2021 Data of two large trials with empagliflozin in patients with heart failure, EMPEROR-Reduced and EMPEROR-Preserved, were pooled for analysis. Milton Packer shares the findings of EMPEROR-Pooled.

HF hospitalizations reduced by SGLT2 inhibitor across broad range of ejection fractions

News - Aug. 27, 2021

ESC 2021 EMPEROR-Pooled was a pooled analysis of the data from EMPEROR-Reduced and EMPEROR-Preserved and showed that empagliflozin, compared to placebo, reduced HF hospitalizations by ~30% in patients with HF across a range of LVEF from <25% to <65%.